Regeneron loses bid to block Amgen's launch of Eylea biosimilar
The U.S. Court of Appeals for the Federal Circuit rejected Regeneron's request to block the launch during its appeal of a related decision for Amgen in a patent case in West Virginia, per a Reuters report.